

## **EXHIBIT “B”**

### **J.T. Thorpe Settlement Trust Claim Report As of December 31, 2007**

This report is submitted pursuant to Section 2.2 (c) (ii) of the Third Amendment to and Complete Restatement of J.T. Thorpe Settlement Trust Agreement, which requires the Trust to file with the Bankruptcy Court a summary of the number and type of claims disposed of during the period covered by the financial statements (“Accounting Period”). This report summarizes the Trust’s processing of claims liquidated under supervision of the Bankruptcy Court (“Pre-Confirmation Liquidated Claims”) and claims received since June 29, 2006, the Effective Date of the Trust (“Trust Claims”).

#### **Pre-Confirmation Liquidated Claims**

In 2006, the Trust implemented a procedure to pay the Pre-Confirmation Liquidated Claims (“PCLP Claims”) in accordance with the Plan, the Trust Distribution Procedures, the Confirmation Order, the January 27, 2006, Order Liquidating Asbestos Related Claims, and the Agreement Regarding Initial Payment Percentage entered into on June 29, 2006, by the Trust Advisory Committee and the Futures Representative. The Agreement Regarding Initial Payment Percentage provided that the Initial Payment Percentage was to be 50% of the total liquidated claim value.

During the Accounting Period, 120 PCLP Claims were paid in the total amount of \$2,280,061.53. The Trust has not yet received proper releases for 54 PCLP Claims in the total amount of \$643,855.72. That amount is based upon the current Payment Percentage, which remained at 50% of the total liquidated claim value in 2007.

#### **Trust Claims**

The following includes claims received and disposed of from January 1, 2007, through December 31, 2007, in accordance with the J.T. Thorpe Case Valuation Matrix and Order Approving Motion to Amend Plan to Modify Base Case Values Contained in Case Valuation Matrix (“Matrix”) and the J.T. Thorpe, Inc., a California corporation/J.T. Thorpe, Inc., a dissolved California corporation/Thorpe Holding Company, Inc., a California corporation/Thorpe Technologies, Inc., a California corporation Asbestos Personal Injury Settlement First Amendment to and Complete Restatement of Trust Distribution Procedures (“TDP”).

The value of each compensable disease is determined by the Matrix and TDP. Claim compensation is adjusted for individual claimants based upon tort related individual characteristics, including, but not limited to: age, marital status, dependents, medical specials, economic loss, exposure location, and whether living at the time of commencement of litigation or filing the claim with the Trust. Each valid claim is awarded a total liquidated value. During the Accounting Period, Trust Claims were paid at the current Payment Percentage of 50% of the total liquidated value.

During the Accounting Period, 1,327 claims were received. Of those 1,327 claims, 1,237 claims were received between June 28, 2007, and December 31, 2007. The majority of those 1,237 claims were placed on hold at the time of submittal based upon the request of the representative law firms. As of December 31, 2007, 417 claims remained on hold; 151 claims were awaiting prima facie review; 337 claims had undergone prima facie review and were awaiting content review; 191 claims had undergone the prima facie and content reviews and were determined to be deficient; and 21 claims had been withdrawn by the representative law firms.

During the Accounting Period, 210 claims were determined to be valid and properly submitted under the Trust claim requirements. Of those 210 claims, 98 claims were paid in the total amount of \$5,406,730.81 and settlement offers remained outstanding for 112 claims.

Based upon the 210 claims, the following chart identifies the average total liquidated values for each compensable disease under the Matrix, comparing the average total liquidated values in 2007, to the Matrix averages.

Compensable Disease	Matrix Averages	2007 Claim Averages
Grade II Non-Malignant	\$3,000.00	\$2,909.07
Grade I Non-Malignant	\$10,000.00	\$9,261.45
Grade I Non-Malignant Enhanced Asbestosis	\$10,000.00	\$15,080.80
Grade I Non-Malignant Serious Asbestosis	\$40,000.00	\$54,826.63
Colo-Rectal	\$25,000.00	\$17,808.29
Esophageal	\$25,000.00	\$12,879.94
Laryngeal	\$25,000.00	\$7,021.31
Other Cancer	\$25,000.00	\$6,281.09
Lung Cancer	\$40,000.00	\$34,454.43
Mesothelioma	\$150,000.00	\$187,053.40